Drug Trial Radar · NCT07288333
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 16, 2026
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
Conditions
- Schizophrenia
Interventions
NBI-1117570Drug
Oral administration
PlaceboDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 35Time frame: Day 35
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Kazanlak, Bulgaria · Recruiting
Neurocrine Clinical Site
Pazardzhik, Bulgaria · Recruiting
Neurocrine Clinical Site
Targovishte, Bulgaria · Recruiting
Neurocrine Clinical Site
Târgu Mureş, Romania · Recruiting
Neurocrine Clinical Site
London, United Kingdom · Recruiting
Neurocrine Clinical Site
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.